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Aneurysmal subarachnoid 
haemorrhage: Effect of CRHR1 
genotype on mental health-related 
quality of life
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Quality of life (QoL) disturbances are common after aneurysmal subarachnoid hemorrhage (aSAH) 
both in physical and mental health domains and their causes are not clearly understood. Corticotropin-
releasing hormone receptor 1 (CRHR1) is involved in stress reactivity and development of mental health 
disturbances after negative life-events. We performed a retrospective cohort study of long-term QoL 
outcomes among 125 surgically treated aSAH patients (2001–2013). QoL was assessed with Short Form 
Health Survey (SF-36) and compared to an age and gender matched general population. Genotyping of 
CRHR1 single nucleotide polymorphisms was performed (Rs7209436, Rs110402, Rs242924) and their 
effect on QoL scores was explored. aSAH patients experienced a reduced quality of life in all domains. 
CRHR1 minor genotype was associated with higher SF-36 mental health (OR = 1.31–1.6, p < 0.05), 
role-emotional (OR = 1.57, p = 0.04) and vitality scores (OR = 1.31–1.38, p < 0.05). Association of all 
studied SNP’s with vitality and Rs242924 with mental health scores remained statistically significant 
after Bonferroni correction. Mental quality of life scores were associated with physical state of patients, 
antidepressant history and CRHR1 genotype. Predisposition to mental health disturbances after 
stressful life-events might be associated with reduced mental QoL after aSAH and selected patients 
could be provided advanced counselling in the recovery phase.
Aneurysmal subarachnoid haemorrhage (aSAH) causes long-term morbidity and leads to reduced quality of life 
(QoL)1. Incidence of aSAH is around 7.9 per 100 000 patient years and is showing a trend of decrease2,3. More 
patients survive the subacute phase and in the long-term almost two-thirds of them are functionally independ-
ent4. Despite survival rates improving up to 65% and physical disability decreasing among survivors, psychosocial 
outcomes after aSAH remain to be notably poor since up to 55% of patients report reduced quality of life years 
after the haemorrhage5. Up to a half of aSAH patients have mental health complaints, including depression and 
anxiety6,7. Only one third of the patients resume the same work8.
The cause of these changes has not been explored, although genetic background may be involved in the devel-
opment of psychosocial impairments. Genes that regulate the function of the stress response system are probable 
moderators of the effect that adverse life events have on development of long-term mental health disturbances9,10. 
Corticotropin-releasing hormone (CRH) is one of the main stress mediators in the central nervous system and 
plays a role in the etiology of emotional disorders11,12. Corticotropin-releasing hormone receptor 1 (CRHR1) gen-
otype has been repeatedly associated with emotional disturbances and response to antidepressant treatment13–15. 
Effect of CRHR1 in major depression is moderated by a history of negative life events16 and CRHR1 genotype is 
associated with cortisol reactivity to stress17–19. The substantial reduction in mental health related QoL after aSAH 
associated with neuroendocrine dysfunction has been previously reported20. Emotional health disturbances are 
connected to quality of life disturbances and explain 23–47% of QOL score reductions in aSAH21.
Few articles have been published on the genetic background of QoL disturbances after aSAH and none have 
studied the effect of the hypothalamic–pituitary–adrenal (HPA)-system22. We hypothesize that CRHR1 genotype 
will influence the mental component of quality of life after aSAH.
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Methods
We performed a retrospective cohort study of long-term outcome in a group of aSAH survivors (n = 125) surgi-
cally treated from January 2001 to November 2013 in a university clinic. All patients diagnosed with aSAH based 
on medical records during this period (n = 467) were included in the study (spontaneous ICH and other SAH 
causes were excluded). We identified 185 survivors with available contact information, who were proposed to 
participate in the study. Exclusion criteria and selection protocol are presented in Fig. 1. Eventually the studied 
group consisted of 125 patients. Blood samples were collected after the interview by the physician. Informed con-
sent was obtained from all participating individuals and all procedures performed in this study involving human 
participants were in accordance with the ethical standards and the latest Helsinki declaration. Tartu University 
ethics committee approval 214/T-2/2012 was given for performing this study.
General management. All patients were admitted during the acute phase of the disease. The diagnosis of 
aSAH was confirmed by computed tomography (CT) or lumbar puncture, and aneurysm location was assessed 
by CT-angiography or digital subtraction angiography. All patients were managed according to general guidelines 
and our protocol is previously published21. Patients were initially treated in a neurointensive care unit. Almost all 
patients were acutely operated upon, preferably via a pterional approach, and the aneurysms were clipped using 
standard microsurgical techniques. Endovascular procedures were preferentially performed in a separate institu-
tion during this time and due to this our study includes a series of clipped patients.
Procedure. Clinical variables, including Hunt and Hess grade (HH)23, which is a grading system designed 
to predict prognosis and outcome in aSAH, were recorded in medical histories during admission. Remaining 
data was collected during the follow-up evaluation, when patients were interviewed in person with a structured 
questionnaire. Patient clinical recovery was evaluated according to the modified Rankin Score (mRS)24. Patients 
were also questioned about treatment for emotional disorders after aSAH, comorbidities, education and social 
living situation (living with family/someone else or alone). Short Form Health Survey (SF-36) was used to assess 
the health-related quality of life (HRQoL).
SF-36 is widely used in clinical outcome research and is a validated instrument to assess general QoL. SF-36 
consists of 36 questions and measures eight scales: physical functioning, role-physical, bodily pain, general health, 
vitality, social functioning, role-emotional, and mental health25,26. SF-36 scores are transformed by assignment of 
predefined weights to the different items and calculated separately for each scale. Results can range from 0 (low 
QoL) to 100 (high QoL). Component scores are separately calculated for mental and physical health. SF-36 ques-
tionnaire has been added as Supplementary Material. Data of the study group was compared with correspond-
ing values from an age-matched and gender-matched group of general population (996 subjects) obtained from 
respondents of a health survey of 1,989 individuals.
Genotyping. The genomic DNA was extracted from venous blood samples in 4 ml EDTA containing vac-
cuettes by using the standard salting-out method. The EDTA tubes were stored at −20C until DNA extraction. 
Isolated DNA was dissolved in Tris-EDTA (TE) buffer. The purity and concentrations of the DNA were meas-
ured by a spectrophotometer (NanoDrop, ND-1000). The gDNA samples were aliquotted and stored at −80C 
until usage27. Genotyping of marker single nucleotide polymorphisms (SNP) rs7209436, rs110402, rs242924 and 
rs242939 was carried out by using TaqMan SNP Genotyping Assay (Applied Biosystems, Foster City, CA, USA), 
which is a multiplex endpoint assay that detects variants of a single nucleic acid sequence. PCR reactions were run 
Figure 1. Study Flow Diagram.
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on the ViiA7 instrument (Applied Biosystems, Foster City, CA, USA) by using the following cycling parameters: 
after the first step at 95C for 10 minutes, 40 cycles of denaturation at 92C for 15 seconds and extension at 60C for 
1 minute. Genomic DNA (20 ng/ul) was amplified in a total volume of 10 ul containing 1× Amplification Master 
Mix (Applied Biosystems, Foster City, CA, USA) and 1× probe. Genotypes were analysed by using the allelic 
discrimination function of the system (Table 1).
Statistics. Student’s t-test was used to determine the associations between the subscale scores of the question-
naires and clinical/sociodemographic factors and compare the SF-36 mean scores of the patients with age and 
gender matched general population. All continuous variables were controlled for normality using Shapiro-Wilk’s 
W test. Beta-binomial regression analysis was performed to describe the association of CRHR1 genotype with 
SF-36 scale scores and calculate odds ratios. In the SNP analysis we chose between additive/dominant/recessive 
model based on the AIC (Akaike information criterion) of the unadjusted model. In the analysis of SF-36 results, 
an odds ratio (OR) higher than 1, indicates a better quality of life in the respective group (recessive model – minor 
allele homozygote; dominant model – major allele homozygote; additive model – OR for heterozygotes, which is 
multiplied in case of minor allele addition); odds ratio lower than 1 indicates a reduced outcome in SF-36 scales. 
More precisely, OR shows what is the probability of receiving a higher score in the selected scale by 1 point (1 
point bring equal to 5 points in physical functioning, vitality, general health scales; 25 points in role-physical 
scale; about 11 points in pain scale; about 33 points in role-emotional scale, 12,5 points in social functioning scale 
and about 8 points in emotional wellbeing scale)28,29. Results were considered significant if p < 0.05. The p-values 
that survived the Bonferroni correction are marked in bold. Pearson’s correlation and multiple logistic regression 
models were used to study the impact of genotype (frequency of minor alleles), sociodemographic and clinical 
factors on SF-36 scores. Statistical analysis was performed with Stata 14.2 (StataCorp LLC) and SPSS 24 (IBM).
Results
Patient and aSAH characteristics are presented in Table 2. Most were female (70%, n = 88) and the mean age at 
the time of the hemorrhage was 54 years (SD ± 13; range 24–82 years). The mean time between initial admission 
and the study was 4 years (SD ± 2.8; range 1–13 years). 51 patients (41%) were evaluated later than 3 years from 
ictus. Most of the patients (78%) had more than 10-years of education. Only 1 patient had a previous diagnosis 
of depression based on the medical histories available from 2009. The mean age of the patients at the time of 
follow-up was 58 years (SD ± 12, range 26–82). 78% (n = 97) of the patients were living with family or somebody 
else. 41% (n = 51) of the patients required daily help. The most common comorbidities were hypertension (67%), 
joint pain (14%) and diabetes (7%). 24% (n = 30) saw a psychologist or psychiatrist and 38% (n = 30) used anti-
depressants during recovery. There was no statistically significant difference between minor and major CRHR1 
genotypes and sociodemographic characteristics.
Of the patients, 55% (n = 68) had a mRS score of 0–2 and 38% (n = 48) had a score of 3. mRS score was worse 
among women (2.5 (SD = 0.8) vs 2.1 (SD = 0.8), p = 0.019) and those requiring daily help (3.1 (SD = 0.5) vs 2.0 
(SD = 0.7), p < 0.001).
Quality of life scores. Quality of life scores of patients measured with SF-36 were significantly lower than 
the general population scores on all scales, except mental health (Table 3). Physical health scores and role limita-
tion scores due to physical and emotional problems were affected the most. The mean SF-36 summary measures 
were: physical health component score (PCS-36) - 43 (SD ± 9.6) and mental health component score (MCS-36) 
- 48.6 (SD ± 9.4).
Being older than 55 years old at ictus was associated with a worse physical functioning score (mean 54 
(SD ± 25.4) vs 68 (SD ± 25), p = 0.003) and a worse PCS-36 score (mean 40.6 (SD ± 9.4) vs 44.6 (SD ± 9.5), 
p = 0.024).
Being female was associated with a worse physical functioning score (mean 56.9 (SD ± 26.4) vs 76.6 
(SD ± 19.1), p < 0.001); role-physical score (mean 32.4 (SD ± 38.6) vs 51.4 (SD ± 45.6), p = 0.019); mental health 
score (mean 64.9 (SD ± 18.9) vs 74.1 (SD ± 13.7), p = 0.08) and a worse PCS-36 score (mean 41.6 (SD ± 9.2) vs 
46.8 (SD ± 9.5), p = 0.005).
Having more than 3 years from aSAH to evaluation was associated with a worse physical functioning score 
(mean 58.3 (SD ± 26.7) vs 67.4 (SD ± 24.5), p = 0.048); a worse general health score (mean 43 (SD ± 20.5) vs 54.2 
(SD ± 21.1), p = 0.003); and a worse PCS-36 score (mean 40.8 (SD ± 8.8) vs 45.4 (SD ± 9.9), p = 0.008). The dif-
ference in physical functioning score became statistically insignificant after adjustment for age.
Hypertension was associated with a worse physical functioning score (mean 58.9 (SD ± 25) vs 70.9 (SD ± 26.3), 
p = 0.018). Diabetes was also associated with a worse physical functioning score (mean 40 (SD ± 24.1) vs 64.6 
(SD ± 25.4), p = 0.016). Having joint pains or rheumatoid arthritis was associated with a worse role-physical score 
(mean 18.1 (SD ± 26.9) vs 41.5 (SD ± 42.8), p = 0.004).
SNP Genotype (n)
Minor 
allele (n)
Major 
allele (n)
Rs7209436 C/C (34) C/T (69) T/T (22) T (91) C (103)
Rs110402 G/G (29) A/G (68) A/A (28) A (96) G (97)
Rs242924 G/G (31) G/T (67) T/T (27) T (94) G (98)
Table 1. CRHR1 allele distribution (n = 125). Abbreviations: CRHR1 - corticotropin-releasing hormone 
receptor 1, SNP– single nucleotide polymorphism.
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mRS score was negatively correlated to all SF-36 scales with −0.62 for physical functioning, −0.47 for 
role-physical, −0.45 for general health and −0.45 for role-emotional (p < 0.001). Correlations with mental health, 
vitality, social functioning scales and pain were below −0.4 (p < 0.001).
Association of CRHR1 genotype with SF-36 outcomes. In beta-binomial regression analysis we 
explored the association of CRHR1 genotype with SF-36 quality of life scores (Table 4). CRHR1 minor alleles 
(rs7209436, rs110402, and rs242924) were associated with higher mental health scores (OR = 1.31 − 1.6, p < 0.05) 
in additive and recessive models; and higher vitality scores (OR = 1.31 − 1.38, p < 0.05) in the additive model. 
Rs7209436 minor alleles were associated with a higher role-emotional score (OR = 1.57, 95% CI, 1.01–2.44, 
p = 0.044) in the additive model and rs110402 major alleles with a lower role-emotional score (OR = 0.43, 95% 
CI, 0.21–0.87, p = 0.019) in the dominant model. The results remained statistically significant after adjustment for 
gender, neurological state at admission (HH), patient age and time from aSAH to evaluation.
Effect of CRHR1 genotype on mental health (Rs242924) and vitality scales (all SNP’s) remained statisti-
cally significant after Bonferroni correction for multiple comparisons. Homozygotes for Rs242924 minor allele 
had higher mental health scores (OR = 1.6, 95% CI, 1.14–2.24, p = 0.007). Homozygotes for minor alleles of 
Rs7209436 (OR = 1.9, p = 0.002), Rs110402 (OR = 1.69, p = 0.008) and Rs242924 (OR = 1.77, p = 0.005) had 
higher vitality scores.
Characteristic N %
Male 37 30
Female 88 70
Hunt Hess score
1 17 14
2 66 53
3 23 18
4 14 11
5 5 4
Aneurysm location
ICA 40 32
AcomA 44 35
MCA 22 18
ACA 8 6
BA 9 7
VA 2 2
Intracerebral haemorrhage 22 18
Symptomatic vasospasm 34 27
Hydrocephalus
acute 43 34
chronic 14* 11
Modified Rankin Score
0 4 3
1 7 6
2 57 46
3 49 39
4 8 6
Table 2. Patient (n = 125) and aSAH characteristics. Abbreviations: ICA internal carotid artery, AcomA 
anterior communicating artery, MCA middle cerebral artery, ACA anterior cerebral artery, BA basilar 
artery, VA vertebral artery, aSAH aneurysmal subarachnoid haemorrhage. *These 14 patients required 
ventriculoperitoneal shunting after aSAH.
SF-36 scales
Mean aSAH 
(n = 125)
SD 
aSAH
Mean population 
(n = 996) SD population p
Physical Functioning 62.8 25.9 79 25.8 <0.001
Role-Physical 38 41.4 71.4 39.1 <0.001
Bodily Pain 66.2 27.7 72.6 26.4 0.008
General Health 48.6 21.4 56.3 19.2 <0.001
Vitality 51.3 20 55 18.9 0.03
Social Functioning 72.1 24.5 77.4 28.6 0.01
Mental Health 67.7 17.9 69.4 17.8 0.31
Role-Emotional 53.1 42 76.3 36.8 <0.001
Table 3. Short Form Health Survey 36 results among patients and gender/age matched general population. 
Abbreviations: SF-36 - Short Form Health Survey 36, aSAH – aneurysmal subarachnoid haemorrhage, SD - 
standard deviation, p – P value.
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Patients with more minor alleles of rs7209436, rs110402, and rs242924 had higher mental QoL scores. 
Homozygotes for minor allele of Rs242924 had a higher mental health score compared to major allele carriers - 76 
vs 66. Homozygotes for minor alleles of Rs7209436, Rs110402 and Rs242924 had higher vitality scores (60 vs 43; 
58 vs 44; and 58 vs 44, respectively). Same trend is observable for other alleles in Table 5. rs242939 did not show 
a statistically significant association with SF-36 scores. TAT-haplotype, formed by the three minor alleles, did not 
show any statistically significant effect on the quality of life scores.
Factors influencing mental QoL. The best multiple regression analysis models for SF-36 scales associated 
with CRHR1 genotype (Table 6) included mRS score, physical health component score, antidepressant usage 
history and CRHR1 genotype (number of minor alleles), with R2 = 0.36 for role-emotional, R2 = 0.32 for vitality 
and R2 = 0.3 for mental health score, all p < 0.001 (Table 6). Minor allele count of Rs110402 was associated with 
role-emotional score (β = 0.15, p = 0.044) and of Rs7209436 with vitality score (β = 0.23, p = 0.003). PCS-36 score 
was associated with role-emotional (β = 0.45, p < 0.001), vitality (β = 0.5, p < 0.001) and mental health scores 
(β = 0.26, p = 0.005). mRS score was associated with role-emotional (β = −0.19, p = 0.032) and mental health 
scores (β = −0.23, p = 0.013). Antidepressant usage history was associated with mental health score (β = −0.23, 
p = 0.007). Sociodemographic factors, aneurysm location and comorbidities were not associated with SF-36 men-
tal scale outcomes in multiple regression analysis.
Discussion
In this retrospective cohort study, we describe the effect of CRHR1 gene polymorphisms on long-term quality of life 
outcomes after aSAH measured with SF-36 questionnaire. Beta-binomial regression analysis showed that CRHR1 
genotype (rs7209436, rs110402, and rs242924) significantly affected mental quality of life outcomes after aSAH in 
studied patients. CRHR1 minor genotype carriers had higher quality of life scores in mental health, role-emotional 
and vitality scales, compared to the more common alleles. Rs110402 major genotype increased the risk of a worse 
score in role-emotional scale. Results remained statistically significant after adjustment for gender, neurological 
state at admission (HH), patient age and time from aSAH to evaluation. Effect of CRHR1 genotype on mental health 
(Rs242924) and vitality scales (all SNP’s) remained statistically significant after Bonferroni correction.
SNP Allele Model OR 95% CI p OR* 95% CI* p*
Mental health
Rs7209436 Minor Additive 1.31 1.07–1.6 0.009 1.31 1.07–1.6 0.009
Rs110402 Minor Additive 1.29 1.06–1.57 0.011 1.26 1.04–1.54 0.019
Rs242924 Minor Recessive 1.6 1.14–2.24 0.006 1.59 1.14–2.22 0.007
Vitality
Rs7209436 Minor Additive 1.38 1.13–1.7 0.002 1.38 1.13–1.69 0.002
Rs110402 Minor Additive 1.31 1.07–1.6 0.008 1.31 1.07–1.6 0.009
Rs242924 Minor Additive 1.33 1.09–1.62 0.005 1.32 1.08–1.62 0.006
Role-emotional
Rs7209436 Minor Additive 1.57 1.01–2.44 0.044 1.53 0.98–2.4 0.063
Rs110402 Major Dominant 0.43 0.21–0.87 0.019 0.44 0.22–0.91 0.026
Table 4. Association of genotype with Short Form Health Survey 36 scales (only statistically significant results 
are reported). Abbreviations: SNP – single nucleotide polymorphism, OR-odds ratio, CI-confidence interval, 
p –P-value. *-values adjusted for sex, Hunt Hess score, patient age and time of evaluation from aSAH. P-values 
that survived the Bonferroni correction are marked with bold.
Genotype Mental health Vitality Role-emotional
Rs7209436
MM 63.5 ± 24.0 43.4 ± 15.3 41.2 ± 40.5
mM 67.2 ± 18.5 52.5 ± 21.4 55.6 ± 43.1
mm 75.5 ± 15.4 59.5 ± 17.6 63.6 ± 36.1
Rs110402
MM 63.3 ± 17.4 44.0 ± 15.1 36.8 ± 39.5
mM 66.6 ± 18.5 51.7 ± 22.1 55.9 ± 42.6
mm 74.7 ± 14.9 57.9 ± 16.3 63.1 ± 38.2
Rs242924
MM 65.9 ± 17.9 43.7 ± 15.3 n/a
mM 65.3 ± 18.3 52.0 ± 21.9 n/a
mm 75.7 ± 14.2 58.1 ± 16.6 n/a
Table 5. Average scores of SF-36 QoL scales associated with CRHR1 genotype according to major and minor 
alleles. Abbreviations: n/a – not associated. MM – homozygote for major allele, mM – heterozygote, mm – 
homozygote for minor allele.
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In our study, aSAH patients scored significantly lower on all SF-36 scales when compared to age and gender 
matched general population, except mental health where the difference did not reach statistical significance. We 
describe a more pronounced effect of aSAH on the physical component of QoL. Age, female gender, time from 
aSAH and comorbidities were associated with worse physical scale and general health scores. Female gender was 
associated with worse mental health. All SF-36 scales were negatively correlated to mRS score. Compared to a 
Swedish population studied with SF-36 after ischemic stroke, aSAH patients scored higher on physical function, 
but lower in mental health scales30. When compared to a group of 4-year myocardial infarction survivors aged 
under 65 years the biggest difference presented in role-limitation scores, with aSAH patients scoring lower31. 
Our patient group scored somewhat lower in the mental health scale of SF-36 than the age and gender matched 
general population, but the difference did not reach statistical significance. Elsewhere we have shown that when 
studied with a validated emotional health survey (EST-Q), which is based on DSMIV and ICD-10 diagnostic cri-
teria, the same patient group exhibited an almost 3 times higher prevalence of depression and anxiety symptoms 
as an age and gender matched population. SF-36 mental health scale score consists of five questions (24–26, 28, 
30). The shortage of statistical difference in detailed analysis of mental health scale depended on a better result of 
the study population in question 30 (amount of time spent being happy in the last 4 weeks). Patients scored higher 
than the general population on this sole question – 51 (SD ± 25.3) vs 46.4 (SD ± 27.8), p = 0.03. When question 
30 was excluded and the remaining four questions averaged, the patient group scored significantly lower than the 
general population – 71.8 (SD ± 19.5) vs 75.2 (SD ± 18.4), p = 0.03.
Role-emotional and vitality scores were substantially lower among aSAH patients and were significantly 
affected by CRHR1 genotype. Role-emotional scale shows the subjective limitations people add to daily activities 
due to perceived mental problems. Vitality scale is a measure of energy/fatigue and it is often reduced after severe 
illness32. Fatigue could present in patients due to a state of mental exhaustion from having to deal with the pro-
cesses of rehabilitation and adaptation to a new situation.
The three scales of SF-36, that reflect on the mental component of quality of life, were affected by CRHR1 gen-
otype. Other factors that influenced the results, based on the multiple regression analysis, were modified Rankin 
scale, PCS-36 score and history of antidepressant usage. Two thirds of the variables affecting mental QoL scores 
remained unknown. It was previously reported that depression and fatigue have a significant role in mental QoL 
score reductions measured with SF-36, explaining 42% to 47% of the variance21. Involvement of CRHR1 genotype 
in the present study might be explained by its association with mental health disease. CRHR1 receptor is impor-
tant in regulation of HPA-axis reactivity to stress and its genotype moderates the risk of mental health disorders 
after stressful life events16,33, including severe illness and intensive care treatment. CRHR1 (rs1876831) genotype 
has been associated with post-traumatic stress disorder and depression symptoms in critical illness survivors34. 
This warrants for further research and separate evaluation of specific QoL modalities in patients after aSAH with 
focus on mental health.
Despite advances in diagnosis and early management of aSAH, outcomes for most patients remain suboptimal 
and long-term sequelae of the disease may be unrecognized. Quality of life in aSAH patients has been linked to 
both physical and mental health disturbances in the long-term5,35–39. Variations exist in the capacity and timing 
of recovery in different components of quality of life after aSAH, with emotional health requiring more time to 
improve40. It was reported that productivity losses related to aSAH reached £278.9 million in the UK in 200541. 
Neuropsychological disturbances can affect the ability of patients to return to work42,43, but proper rehabilitation 
can lead to reintegration in the long term44. We suggest that role of CRHR1 genotype warrants more research as it 
could help provide optimal rehabilitation and neuro-psychological support for aSAH patients.
Study limitations. Our study consisted of 125 subjects and was a retrospective design. A selection bias 
due to loss of follow up exists and is related to the longevity of the study, social factors and patient participation. 
Although, we describe an association of CRHR1 genotype with mental QoL, our study might be underpowered to 
draw certain conclusions. Our findings require replication in a larger cohort. It is unknown whether the studied 
SNP-s are functional, or they are in linkage disequilibrium with other regions. Despite mental health diagnosis 
being extractable from the national database, we do not know the full extent of previous emotional problems 
in our patient group. We lack information regarding the cognitive profile of the patients, but none of them had 
severe disabilities when interviewed. SF-36 is a generic questionnaire that measures multiple modalities of quality 
Variables B SE β p-value R2
Role-Emotional
PCS-36 1.96 0.37 0.45 <0.001
0.36mRS −15.56 7.17 −0.19 0.032
Rs110402 9.43 4.64 0.15 0.044
Vitality
PCS-36 1.04 0.16 0.5 <0.001
0.32
Rs7209436 6.85 2.3 0.23 0.003
Mental Health
PCS-36 0.48 0.17 0.26 0.005
0.3Antidepressants −8.41 3.06 −0.23 0.007
mRS −8.13 3.23 −0.23 0.013
Table 6. Multiple regression for SF-36 scales associated with CRHR1 genotype.
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of life. It has a correlation around 0.7 with other QoL assessment tools45–47. Differences exist in results among QoL 
questionnaires and subscales exhibit ceiling and floor effects30,48. Cultural factors can also influence outcomes.
conclusion
Results of our study suggest that CRHR1 genotype could influence mental quality of life outcomes after aSAH. 
rs7209436, rs110402, and rs242924 minor genotype significantly increased SF-36 mental health, role emotional 
and vitality scale scores This effect might be explained by CRHR1 role in the pathogenesis of emotional disorders 
and stress reactivity. New and improved biomarkers are needed to predict, diagnose and treat the long-term 
consequences of aSAH. Such biomarkers could help identify patients who would benefit from early neuropsycho-
logical rehabilitation.
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